Multilineage reconstitution*
| G-CSF-mobilized stem cells† . | Ly-5.1 CD34− bone marrow stem cells of primary recipients‡ . | |||||||
|---|---|---|---|---|---|---|---|---|
| CD34−cells . | CD34+ cells . | |||||||
| G + M . | T . | B . | G + M . | T . | B . | G + M . | T . | B . |
| 0 | 0 | 0 | 31 | 31 | 89 | 7 | 8 | 1 |
| 0 | 0 | 0 | 21 | 38 | 57 | 1 | 1 | 1 |
| 26 | 43 | 56 | 20 | 43 | 46 | 34 | 7 | 1 |
| 74 | 16 | 4 | 15 | 44 | 30 | 2 | 5 | 1 |
| 0 | 0 | 0 | 29 | 42 | 85 | 69 | 56 | 46 |
| 18 | 17 | 43 | 66 | 32 | 61 | 1 | 1 | 0 |
| 35 | 28 | 38 | 54 | 44 | 65 | 3 | 4 | 1 |
| 29 | 45 | 42 | 20 | 2 | 1 | |||
| 1 | 1 | 1 | ||||||
| 3 | 1 | 15 | ||||||
| G-CSF-mobilized stem cells† . | Ly-5.1 CD34− bone marrow stem cells of primary recipients‡ . | |||||||
|---|---|---|---|---|---|---|---|---|
| CD34−cells . | CD34+ cells . | |||||||
| G + M . | T . | B . | G + M . | T . | B . | G + M . | T . | B . |
| 0 | 0 | 0 | 31 | 31 | 89 | 7 | 8 | 1 |
| 0 | 0 | 0 | 21 | 38 | 57 | 1 | 1 | 1 |
| 26 | 43 | 56 | 20 | 43 | 46 | 34 | 7 | 1 |
| 74 | 16 | 4 | 15 | 44 | 30 | 2 | 5 | 1 |
| 0 | 0 | 0 | 29 | 42 | 85 | 69 | 56 | 46 |
| 18 | 17 | 43 | 66 | 32 | 61 | 1 | 1 | 0 |
| 35 | 28 | 38 | 54 | 44 | 65 | 3 | 4 | 1 |
| 29 | 45 | 42 | 20 | 2 | 1 | |||
| 1 | 1 | 1 | ||||||
| 3 | 1 | 15 | ||||||
G+M indicates granulocytes and/or macrophages; T, T lymphocytes; B, B lymphocytes.
Numbers indicate the percentage of cells within each lineage that expressed Ly-5.1. Peripheral blood nucleated cells were stained with anti-Ly-5.1 and either anti-Gr-1 and anti-Mac-1, anti-Thy-1.2, or anti-B220.
Engraftment at 4 months posttransplantation by 2 × 105 Lin− CD34− or 1 × 104 Lin− CD34+ granulocyte colony-stimulating factor (G-CSF)-mobilized cells shown in Figure 2.
Engraftment at 5 months posttransplantation by 1 × 104 Ly-5.1 CD34− bone marrow cells of primary recipients shown in Figure 6.